2018-2023 Global Mitomycin C Consumption Market Report
In this report, LP Information covers the present scenario (with the base year being 2017) and the growth prospects of global Mitomycin C market for 2018-2023.
Mitomycin C market, Mitomycin C is an antibiotic which acts as a double-stranded DNA alkylating agent. It covalently crosslinks DNA, inhibiting DNA synthesis and cell proliferation It acts by way of reductive activation either through low pH or NAD(P)H:quinone oxidoreductase (DT-diaphorase) or NADH cytochrome c reductase (Mao et al.; Cummings et al.).
In the last several years, Global market of Mitomycin C was experienced an upward trend rapidly, with an average growth rate of 4.76%. In 2016, Global Revenue of Mitomycin C is nearly 119.83 M USD; the actual production is about 17370 K Unit.
The global average price of Mitomycin C is in the increasing trend, from 6.30 USD/Unit in 2012 to 6.90 USD/Unit in 2016. With the situation of global economy, prices will be in increasing trend in the following five years.
The classification of Mitomycin C includes 2 Mg, 10 Mg, 40 Mg, and others. The proportion of 2 Mg in 2016 is about 41.5%, and the proportion is in decreasing trend from 2012 to 2016.
Mitomycin C is widely used in Cancer Treatment, Ophthalmic Use, and other field. The most proportion of Mitomycin C is Cancer Treatment, and the proportion in 2016 is 69%. The trend of Cancer Treatment is decreasing.
Japan is the largest supplier of Mitomycin C, with a production market share nearly 26.5% in 2016. India is the second largest supplier of Mitomycin C Media, enjoying production market share nearly 25% in 2016.
North America is the largest consumption place, with a consumption market share nearly 36% in 2016. Following North America, Europe is the second largest consumption place with the consumption market share of 32.6%.
Market competition is not intense. Kyowa-kirin, Intas Pharmaceuticals, Teva, Bristol-Myers Squibb, Aspen, Speciality European Pharma, etc. are the leaders of the industry.
Over the next five years, LPI(LP Information) projects that Mitomycin C will register a -2.3% CAGR in terms of revenue, reach US$ 100 million by 2023, from US$ 120 million in 2017.
This report presents a comprehensive overview, market shares, and growth opportunities of Mitomycin C market by product type, application, key manufacturers and key regions.
To calculate the market size, LP Information considers value and volume generated from the sales of the following segments:
Segmentation by product type:
2 Mg
10 Mg
40 Mg
Other
Segmentation by application:
Cancer Treatment
Ophthalmic Use
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Spain
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market. The key manufacturers covered in this report:
Kyowa-kirin
Intas Pharmaceuticals
Teva
Bristol-Myers Squibb
Aspen
Speciality European Pharma
Alkem Laboratories
Varifarma
APOGEPHA
In addition, this report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key manufacturers and the market as a whole. It also analyzes key emerging trends and their impact on present and future development.
Research objectives
To study and analyze the global Mitomycin C consumption (value & volume) by key regions/countries, product type and application, history data from 2013 to 2017, and forecast to 2023.
To understand the structure of Mitomycin C market by identifying its various subsegments.
Focuses on the key global Mitomycin C manufacturers, to define, describe and analyze the sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years.
To analyze the Mitomycin C with respect to individual growth trends, future prospects, and their contribution to the total market.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
To project the consumption of Mitomycin C submarkets, with respect to key regions (along with their respective key countries).
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
To strategically profile the key players and comprehensively analyze their growth strategies.
Mitomycin C market, Mitomycin C is an antibiotic which acts as a double-stranded DNA alkylating agent. It covalently crosslinks DNA, inhibiting DNA synthesis and cell proliferation It acts by way of reductive activation either through low pH or NAD(P)H:quinone oxidoreductase (DT-diaphorase) or NADH cytochrome c reductase (Mao et al.; Cummings et al.).
In the last several years, Global market of Mitomycin C was experienced an upward trend rapidly, with an average growth rate of 4.76%. In 2016, Global Revenue of Mitomycin C is nearly 119.83 M USD; the actual production is about 17370 K Unit.
The global average price of Mitomycin C is in the increasing trend, from 6.30 USD/Unit in 2012 to 6.90 USD/Unit in 2016. With the situation of global economy, prices will be in increasing trend in the following five years.
The classification of Mitomycin C includes 2 Mg, 10 Mg, 40 Mg, and others. The proportion of 2 Mg in 2016 is about 41.5%, and the proportion is in decreasing trend from 2012 to 2016.
Mitomycin C is widely used in Cancer Treatment, Ophthalmic Use, and other field. The most proportion of Mitomycin C is Cancer Treatment, and the proportion in 2016 is 69%. The trend of Cancer Treatment is decreasing.
Japan is the largest supplier of Mitomycin C, with a production market share nearly 26.5% in 2016. India is the second largest supplier of Mitomycin C Media, enjoying production market share nearly 25% in 2016.
North America is the largest consumption place, with a consumption market share nearly 36% in 2016. Following North America, Europe is the second largest consumption place with the consumption market share of 32.6%.
Market competition is not intense. Kyowa-kirin, Intas Pharmaceuticals, Teva, Bristol-Myers Squibb, Aspen, Speciality European Pharma, etc. are the leaders of the industry.
Over the next five years, LPI(LP Information) projects that Mitomycin C will register a -2.3% CAGR in terms of revenue, reach US$ 100 million by 2023, from US$ 120 million in 2017.
This report presents a comprehensive overview, market shares, and growth opportunities of Mitomycin C market by product type, application, key manufacturers and key regions.
To calculate the market size, LP Information considers value and volume generated from the sales of the following segments:
Segmentation by product type:
2 Mg
10 Mg
40 Mg
Other
Segmentation by application:
Cancer Treatment
Ophthalmic Use
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Spain
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market. The key manufacturers covered in this report:
Kyowa-kirin
Intas Pharmaceuticals
Teva
Bristol-Myers Squibb
Aspen
Speciality European Pharma
Alkem Laboratories
Varifarma
APOGEPHA
In addition, this report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key manufacturers and the market as a whole. It also analyzes key emerging trends and their impact on present and future development.
Research objectives
To study and analyze the global Mitomycin C consumption (value & volume) by key regions/countries, product type and application, history data from 2013 to 2017, and forecast to 2023.
To understand the structure of Mitomycin C market by identifying its various subsegments.
Focuses on the key global Mitomycin C manufacturers, to define, describe and analyze the sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years.
To analyze the Mitomycin C with respect to individual growth trends, future prospects, and their contribution to the total market.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
To project the consumption of Mitomycin C submarkets, with respect to key regions (along with their respective key countries).
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
To strategically profile the key players and comprehensively analyze their growth strategies.
Frequently Asked Questions
This market study covers the global and regional market with an in-depth analysis of the overall growth prospects in the market. Furthermore, it sheds light on the comprehensive competitive landscape of the global market. The report further offers a dashboard overview of leading companies encompassing their successful marketing strategies, market contribution, recent developments in both historic and present contexts.
- By product type
- By End User/Applications
- By Technology
- By Region
The report provides a detailed evaluation of the market by highlighting information on different aspects which include drivers, restraints, opportunities, and threats. This information can help stakeholders to make appropriate decisions before investing.
Please Select a Format
